ChiCTR-TRC-12001914 版本V1.0 版本创建时间2015/07/29 12:15:41 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-TRC-12001914 

最近更新日期:

Date of Last Refreshed on:

2015-05-05 10:18:45 

注册时间:

Date of Registration:

2012-01-31 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

乳母补充维生素A改善婴儿对乙肝疫苗抗体反应的研究

Public title:

Effects of Vitamin A Supplementation to Lactating Mothers on Infants’ Antibody Response to Hepatitis B Vaccine in China

注册题目简写:

English Acronym:

研究课题的正式科学名称:

乳母补充维生素A改善婴儿对乙肝疫苗抗体反应的研究

Scientific title:

Effects of Vitamin A Supplementation during Lactation on Infants’ Antibody Response to Hepatitis B Vaccine in China

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

汪之顼 

研究负责人:

汪之顼 

Applicant:

Wang, Zhixu 

Study leader:

Wang, Zhixu 

申请注册联系人电话:

Applicant telephone:

+86 25 86862078

研究负责人电话:

Study leader's
telephone:

+86 25 86862078

申请注册联系人传真 :

Applicant Fax:

+86 25 86527613

研究负责人传真:

Study leader's fax:

+86 25 86527613

申请注册联系人电子邮件:

Applicant E-mail:

zxwang@njmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

zxwang@njmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

http://www.njmu.edu.cn/

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

http://www.njmu.edu.cn/

申请注册联系人通讯地址:

江苏省南京市汉中路140号1#楼447室

研究负责人通讯地址:

江苏省南京市汉中路140号1#楼447室

Applicant address:

140 Hanzhong Rd., Nanjing, Jiangsu, China

Study leader's address:

140 Hanzhong Rd., Nanjing, Jiangsu, China

申请注册联系人邮政编码:

Applicant postcode:

210029

研究负责人邮政编码:

Study leader's postcode:

210029

申请人所在单位:

南京医科大学公共卫生学院

Applicant's institution:

Nanjing Medical University School of Public Health

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

No.200823

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

南京医科大学伦理委员会

Name of the ethic committee:

Ethic Committee of Nanjing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2008-04-16 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京医科大学公共卫生学院

Primary sponsor:

Nanjing Medical University School of Public Health

研究实施负责(组长)单位地址:

江苏省南京市汉中路140号

Primary sponsor's address:

140 Hanzhong Rd., Nanjing, Jiangsu, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

瑞士

省(直辖市):

市(区县):

Country:

Swiss

Province:

City:

单位(医院):

雀巢国际基金会

具体地址:

瑞士洛桑581号邮箱 CH-1001,车站广场4号,雀巢基金会

Institution
hospital:

Nestle Foundation

Address:

Nestlé Foundation - Place de la Gare 4 - PO Box 581 - CH-1001 Lausanne, Switzerland

经费或物资来源:

雀巢国际基金会

Source(s) of funding:

Nestle Foundation

研究疾病:

维生素A缺乏症  

Target disease:

Vitamin A deficiency

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

维生素A缺乏在全世界广泛流行,尤其是发展中国家更为严重,导致全球每年60万儿童死亡。我国城乡3~12岁儿童维生素A缺乏和边缘缺乏率达54.4%,农村为60.8%;农村80%以上六月龄内婴儿维生素A营养不良。维生素A补充可显著降低维生素A缺乏地区儿童死亡率,还可促进儿童对多种疫苗的免疫应答。乙肝疫苗接种是我国控制乙肝的最重要措施,但婴幼儿中广泛的V维生素A营养不良是否会制约乙肝疫苗免疫效果,目前尚无研究。本研究将采用随机、双盲、安慰剂对照的现场干预试验,选择150 例农村乳母及其母乳喂养婴儿为研究对象,随机分为三组,从产后两周直到产后六个月,分别给予乳母分次大剂量、每日小剂量维生素A补充以及安慰剂,观察母乳中维生素A含量变化,母乳喂养儿童血清维生素A水平改善,以及婴儿完成三次乙肝疫苗接种后一个月时血清抗乙肝疫苗抗体浓度,分析三组间的差别。结果将有助于阐明我国儿童维生素A营养不良是否制约了乙肝疫苗的免疫效果。  

Objectives of Study:

Vitamin A deficient (VAD) children have impaired immunity. Vitamin A (VA) supplementation has been associated with enhancing anti-body response to tetanus toxoid and diphtheria, measles and Hepatitis B vaccine. VAD is highly prevalent in China, about 39.4% and 44.8% of rural infants under-6-months were VAD and marginal VAD. Meanwhile, the prevalence of Hepatitis B virus infection was about 9.09% in China. Hepatitis B vaccine has been incorporated into China’s National Immunization Program since 2002. But 1.89%~63.06% of young children manifested weak or null response to the vaccine. Thus, research is needed to assess the impact of vitamin A status on response to the vaccine. The overall goal of this study is to assess the effects of maternal VA supplementation during lactation on their offspring’s vitamin A status and immune response to Hepatitis B vaccine. This is a randomized, double-blind, controlled intervention trial. Lactating women (n=150) are recruited before giving birth and randomly assigned to one of the following three groups: 1) large doses VA supplements (60mg) each at 2 weeks and 3 months postpartum; 2) daily VA supplements (1.2 mg) for 6 months; or 3) no any VA supplements. In addition, all of the mothers will be given daily a capsule containing 10 mg alpha-tocopherol and 10μg cholecalciferol in corn oil. Blood samples will be collected from the infants at 1 month after the 3rd Hepatitis B vaccine to analyze plasma anti-Hepatitis B antibody, retinol and acute phase proteins (C-reactive protein and alpha-acid glycoprotein). Maternal venous blood will be collected to analyze plasma retinol concentration at the beginning and the end of the study. Breast milk samples will be collected from the mothers at the beginning, mid and end of the treatment period to analyze breast milk retinol.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

身体健康
无明显妊娠并发症
单胎妊娠
乙肝表面抗原(HBsAg)阴性
所生产的婴儿出生体重正常
无母乳喂养禁忌和限制
打算母乳喂养婴儿
签署书面知情同意书

Inclusion criteria

General healthy;
No obvious pregnancy complications;
Single pregnancy;
Hepatitis B surface antigen (HBsAg) negative;
The birth of babies born with normal weight;
No breastfeeding restrictions;
willing for breastfeeding of baby;
With a signed written informed consent.

排除标准:

患有任何明确诊断的慢性疾病
妊娠期出现各种并发症
双胎及以上妊娠者
乙肝表面抗原(HBsAg)阳性
所生婴儿为早产、低出生体重、巨大儿
患有急性疾病或精神异常不宜母乳喂养者
不打算母乳喂养婴儿者
未签署书面知情同意书

Exclusion criteria:

With any diagnosed chronic diseases;
With any Pregnancy complications;
Birth of twins and above;
Hepatitis b surface antigen (HBsAg) positive;
Birth of preterm, low birth weight and macrosomia;
Any obstacle for breastfeeding;
Not going to breast-feeding the baby;
Without signed written informed consent.

研究实施时间:

Study execute time:

From 2009-11-01 00:00:00 To 2011-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2009-11-01 00:00:00 To 2010-11-01 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

50

Group:

Control group

Sample size:

干预措施:

每日维生素E10mg+维生素D3 10μg

干预措施代码:

Intervention:

10 mg alpha-tocopherol and 10μg cholecalciferol in corn oil per day

Intervention code:

组别:

干预组1

样本量:

50

Group:

Treatment 1

Sample size:

干预措施:

[每3月1次维生素A(视黄醇)60mg] + [每日1次(维生素E10mg)+(维生素D3 10μg)]

干预措施代码:

Intervention:

[10 mg alpha-tocopherol) and (10μg cholecalciferol) in corn oil per day] + [(retinol 60mg) per 3 months]

Intervention code:

组别:

干预组2

样本量:

50

Group:

Treatment 2

Sample size:

干预措施:

每日1次 [维生素A(视黄醇)1.2mg+维生素E10mg+维生素D3 10μg]

干预措施代码:

Intervention:

(1.2mg retinol + 10 mg alpha-tocopherol + 10μg cholecalciferol) in corn oil per day

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

临沂市 

Country:

China

Province:

Shandong

City:

Linyi

单位(医院):

蒙阴县人民医院 

单位级别:

县级 

Institution
hospital:

Mengyin County Hospital

Level of the institution:

County

测量指标:

Outcomes:

指标中文名:

血清维生素A

指标类型:

主要指标

Outcome:

serum retinol concentration

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清抗乙肝病毒抗体

指标类型:

主要指标

Outcome:

Anti-hepatitis B surface antigen

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

母乳中维生素A含量

指标类型:

主要指标

Outcome:

retinol concentration of breast milk

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

实验室保存3年

Fate of sample:

Destruction after use  

Note:

3 years preservation

标本中文名:

乳汁

组织:

Sample Name:

Breast milk

Tissue:

人体标本去向

使用后销毁  

说明

实验室保存3年

Fate of sample:

Destruction after use  

Note:

3 years preservation

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 42 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

现场调查人员对予纳入对象依据入院顺序编号,完成基线调查和干预试验开始前,依据课题设计者提供的计算机生成的随机数字表进行随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

The volunteers were numbered by field investigators on the basis of sequence admitted to hospital, a

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

南京医科大学公共卫生学院

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Nanjing Medical University School of Public Health

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

南京医科大学公共卫生学院

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Nanjing Medical University School of Public Health

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2012-02-04 00:00:00